Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Birch and Grass Pollen Allergy Studies

Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe. With two different indications required, Grass Pollen Allergy and Birch Pollen Allergy, Pharm-Olam completed a comprehensive feasibility program and presented the findings to the sponsor for analysis and approval. Once approved,Pharm-Olam committed to recruit the required patients within 4 months, while adhering to strict inclusion and exclusion criteria.

Click the image to download the full case study